替诺福韦酯和恩替卡韦对慢性乙型肝炎初治患者疗效的荟萃分析

摘要/Abstract

摘要： 目的评价替诺福韦酯(TDF)和恩替卡韦(ETV)对慢性乙型肝炎(CHB)初治患者抗病毒的疗效及安全性。方法对2006年1月至2016年10月在国际生物医学期刊有关TDF和ETV治疗CHB的临床研究进行质量评价,并对相关文献进行荟萃分析。结果共纳入6篇文献。荟萃分析结果显示ETV和TDF抗病毒治疗的HBV DNA转阴率差异无统计学意义[48周时的RR=1.19,95% CI=1.09~1.30;96周时的RR=1.08,95% CI=1.02~1.14];两种药物的ALT复常率及HBeAg血清学转换率同样差异无统计学意义;且两种药物长期使用安全性良好,未观察到严重不良反应。结论 ETV和TDF对CHB核苷(酸)类药物初治患者抗病毒疗效相似,但仍需进一步观察远期治疗的安全性。

关键词: 慢性乙型肝炎, 恩替卡韦, 替诺福韦酯, Meta分析

Abstract: Objective To compare treatment efficacy and safety of tenofovir (TDF) or entecavir (ETV) in nucleoside-nave chronic hepatitis B (CHB) patients using meta-analysis.Methods Published data relevant to TDF or ETV treated CHB patients from January 2006 to October 2016 was enrolled and meta-analyzed. The rate of Hepatitis B virus (HBV) DNA suppression, alanine transaminase (ALT) normalization, and hepatitis B e antigen (HBeAg) seroconversion at week 48 and 96 were reviewed, respectively. Drug safety and resistance were also discussed.Results There were 6 articles involved. The meta-analysis showed no significant differences in HBV DNA suppression rate between the two drugs innave treated CHB patients (TDF vs. ETV: RR= 1.19, 95% CI = 1.09~1.30 and RR=1.08, 95% CI=1.02~1.14 for week 48 and week 96, respectively). Moreover, there were also no differences in ALT normalization rate (4 studies for 48 weeks), HBeAg seroconversion rate (3 studies for 96 weeks) and long-term safety between TDF and ETV, respectively.Conclusion TDF and ETV show similar efficacy in treating nucleoside-nave chronic HBV patients. Nevertheless, the long-term efficacy and safety should be monitored in prolonged therapy.

Key words: Chronic hepatitis B, Entecavir, Tenofovir disoproxil fumarate, Meta-analysis

丁荣蓉,施光峰,张占卿,周新兰. 替诺福韦酯和恩替卡韦对慢性乙型肝炎初治患者疗效的荟萃分析[J]. 肝脏, 2017, 22(5): 400-403.

DING Rong-rong, SHI Guang-feng, ZHANG Zhan-qing, ZHOU Xin-lan. A meta-analysis of comparison of efficacy of tenofovir or entecavir in nucleos(t)ide analogue-naive patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2017, 22(5): 400-403.

参考文献 21

[1]	Sriprayoon T,Lueangarum S,Suwanwela C,et al. Efficacy and safety of Entecavir versus Tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Gastroenterology,2012,1421:S695-S695.
[2]	Sriprayoon T,Mahidol C,Ungtrakul T,et al.Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatol Res,2017,47: E161-E168.
[3]	Shi H,Huang M,Lin G,et al. Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Biomed Res Int,2016,2016:6725073.
[4]	Dogan UB,Kara B, Gumurdulu Y,et al. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol,2012,23:247-252.
[5]	Batirel A,Guclu E,Arslan F,et al. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-na?ve patients with chronic hepatitis B: a multicenter resl-life study. Int J Infect Dis,2014,28:153-159.
[6]	Gao L,Trinh HN,Li J,et al. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther,2014,39:629-637.
[7]	Simsek H,Schiffe E,Goodman Z,et aL.Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection:Results of three pivotal trials.J Hepatol,2006,44:S191.
[8]	Lampertico P. Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. J Hepatol,2006,45:457-460.
[9]	Buti M,Morillas RM,Prieto M,et al. A viral load reduction>3 log at 12 week of Entecavir treatment correlated with HBe seroconversion in HBeAg positive patients. Results from a real-life setting study. Hepatology,2010,52:A409.
[10]	Lampertico P,Vigano M,Soffredini R, et al. Entecavir monotherapy for nuc-nave chronic hepatitis B patients from field practice: high efficacy and favorables afety profile over 3 year. Hepatology,2011,54:A1436.
[11]	Carey I,Nguyen HL,Joe D,et al. Denovo antiviral therapy with nucleos(t)ide analogues in ‘real-life’patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir, entecavir vs. tenofovir therapy. Hepatology,2011,54:A1396.
[12]	Ridruejo E,Adrover R,Cocozzella D,et al. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Prac,2011,65:866-870.
[13]	Lampertico P,Sffredini R,Vigano M, et al. 2 year effectiveness and safety of tenofovir in 302 NUC-nave patients with chronic hepatitis B: a multicenter European study in clinical practice. Hepatology,2011,54:A1433.
[14]	Myung HJ,Jeong SH, Kim JW,et al. Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B. Korean J Hepatol,2010,16:57-65.
[15]	Van Bommel F, de Man RA,Wedemeyer H,et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology,2010,51:73-80.
[16]	Chang TT,Lai CL,Kew Yoon S,et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology,2010,51:422-430.
[17]	Kitrinos KM,Corsa A,Liu Y,et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology,2014,5:434-442.
[18]	Duarte-Rojo A,Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol,2010,3:107-119.
[19]	Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology,2009,49:S185-195.
[20]	Winston J,Deray G,Hawkins T,et al. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis,2008,47:1449-1457.
[21]	Lesi O,McMahon B. Guidelines for the prevention,care and treatmnent of persons with chronic hepatitis B infection. The World Health Organization are available on the WHO web site. MARCH 2015:xxiv.